menu
    • menu

    Company profile for Poxel

    NEW Drugs in Dev: 7
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Poxel, we are a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. We believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including typ...
    At Poxel, we are a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. We believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of our clinical stage pipeline programs address significant targets in the energy metabolism pathways.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PoxelFrance Flag
    Country
    Country
    France
    Address
    Address
    Immeuble Le Sunway 259-261 Avenue Jean Jaurès 69007 Lyon
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.poxelpharma.com/en_us
    Linkedin
    Linkedin
    https://www.linkedin.com/company/poxel
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Poxel Reports Q1 2026 Revenue and Provides Update
    Poxel Reports Q1 2026 Revenue and Provides Update

    20 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-20/poxel-reports-first-quarter-2026-revenue-and-provides-a-business-update

    PHARMIWEB
    20 May 2026
    Share Share
    Poxel Reports Q1 2026 Revenue and Provides Business Update
    Poxel Reports Q1 2026 Revenue and Provides Business Update

    20 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7449901

    FIRSTWORD PHARMA
    20 May 2026
    Share Share
    Poxel Sells PXL770 to Scynexis for Up to $196 Million
    Poxel Sells PXL770 to Scynexis for Up to $196 Million

    31 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260331538575/en/Poxel-Announces-the-Sale-of-PXL770-to-Scynexis-for-a-Total-Amount-of-up-to-%24196-Million

    BUSINESSWIRE
    31 Mar 2026
    Share Share
    Poxel Confirms Drawdown Under Tranche D PDR Bonds
    Poxel Confirms Drawdown Under Tranche D PDR Bonds

    25 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260325001000/en/Poxel-Confirms-the-Drawdown-Under-the-Additional-Tranche-D-PDR-Bond-Issue-as-Part-of-the-Continuation-Plan

    BUSINESSWIRE
    25 Mar 2026
    Share Share
    Poxel Reports its 2025 Revenue and Provides an Update Financial
    Poxel Reports its 2025 Revenue and Provides an Update Financial

    16 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260216011686/en/Poxel-Reports-its-2025-Revenue-and-Provides-an-Update-on-its-Financial-Position

    BUSINESSWIRE
    16 Feb 2026
    Share Share
    Poxel Implements Equity Line With IRIS Capital In Recovery Plan
    Poxel Implements Equity Line With IRIS Capital In Recovery Plan

    03 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260202723908/en/Poxel-Announces-the-Implementation-of-an-Equity-Line-With-IRIS-Capital-as-Part-of-the-Execution-of-the-Recovery-Plan

    BUSINESSWIRE
    03 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search